Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)

University Hospitals Cleveland Medical Center6 enrolled

Overview

Uroxatral (alfuzosin) may not only help BPH symptoms but may also improve sexual function in males with BPH and ED.

The study will consist of a 30 day screening/washout phase at the end of which qualified subjects will be assigned to alfuzosin 10 mg tablets once a day. Subjects will be treated for 90 days. The total duration of the study will be 120 days.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

BPH Erectile Dysfunction

Interventions

Alfuzosin 10 mgDRUG

Eligibility

Sex: MALEMin age: 45 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Males 45-75 years of age * Confirmed diagnosis of BPH/lower urinary tract symptoms (LUTS) and ED * Men with steady partner and who agree to attempt sex once a week. Exclusion Criteria: * Prostate cancer * Prostatitis * Penile disease * Cardiac co-morbidity * Pre-existing co-morbid conditions * History of sensitivity to the drug or similar drugs * Enrollment in another clinical trial * Impaired hepatic function * Impaired renal function * Mental conditions rendering subject unable to understand the study * Subjects not likely to comply with protocol

Locations (1)

University Hospitals of Cleveland

Cleveland, Ohio, United States

Outcomes

Primary Outcomes

Evaluate the medication on erection maintenance

Secondary Outcomes

Assess effect of Uroxatral on BPH and sexual function using questionnaires

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.